Visx leverages excimer laser patent position in non-U.S. licensing pact with Chiron.
This article was originally published in The Gray Sheet
Executive Summary
CHIRON VISION EXCIMER LASER NON-U.S. ROYALTY PAYMENTS TO VISX will be a "single digit" percentage of future unit sales under a patent license agreement signed the week of Sept. 25, Chiron reports. The agreement grants the Chiron subsidiary a worldwide license, excluding the U.S., for use of about 15 patents for laser vision correction that cover the fundamentals of ablation of tissue with ultraviolet light and the specific design of devices.